El Aragon Health Research Institute in collaboration with Master's Degree in Tumor Immunology and Cancer Immunotherapy (ITIC), Immunity, Cancer and Diseases of Infectious Origin or Molecular Basis Program and the Faculty of Medicine, University of Zaragoza They organize on Friday, February 23, 2024 at 12:30 p.m. el Seminar Biomedic «NK cell-based cancer immunotherapy»

Seminar Summary:

Cancer immunotherapy is a therapeutic approach that uses the immune system to fight cancer cells.

Among the various strategies, NK cells (natural killer) play a crucial role. These cells are part of the innate immune system and have the ability to recognize and destroy cancer cells without prior identification. Clinical trials are investigating the use of expanded NK cells ex vivo or genetically modified to improve their cytotoxic capacity and persistence in vivo. These studies seek to determine the safety and effectiveness of NK cell-based therapies in different types of cancer, as well as to identify predictive biomarkers of response. Although still in development, preliminary results suggest promising potential for NK cells as an effective tool in cancer immunotherapy. In our laboratory we are interested in cytokine-induced memory-type NK cells (CIML or cytokine-induced memory-like), which have a longer half-life and greater proliferation, cytokine production and cytotoxicity after re-stimulation, even in the absence of specific antigen recognition. We are beginning to develop CIML NK cell production in GMP and designing the clinical trial to treat patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Speaker:

Dr. Francisco Borrego. Biobizkaia Health Research Institute. Barakaldo.